NCT07198867 - A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 31, 2027

Conditions

Acute Myeloid Leukemia (AML)CAR-T Cell Therapy

Interventions

BIOLOGICAL

A-CAR028

A-CAR028 is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD33 and CLL-1 antigens

Trial Locations (1)

RECRUITING

Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER